文献速递肾癌与肾肿瘤

孤立肾肾肿块的综合管理

Comprehensive Management of Renal Masses in Solitary Kidneys.
PubMed 文献 · Eur Urol Oncol · 2022-12-12

该回顾性研究分析了1975-2022年间1024例孤立肾肾肿块患者,评估部分肾切除术(PN)、根治性肾切除术(RN)、冷冻消融(CA)和主动监测(AS)的管理策略与结局。PN占82%,中位随访53个月,5年无复发生存率PN为83%、CA为80%、RN为72%(PN vs RN p=0.03)。结论认为保肾方法在多数患者中可行且成功,PN常具挑战性但可选择性使用酪氨酸激酶抑制剂(TKIs)辅助。

要点

  • 孤立肾肾肿块患者中82%接受PN,5年无复发生存率为83%。
  • PN后5年透析-free生存率为97%,中位新基线GFR为47 ml/min/1.73 m2。
  • 22例透明细胞肾细胞癌且RENAL评分≥10者使用TKIs辅助PN,91%完成PN。

核心结论

  • 保肾方法在多数孤立肾肾肿块患者中可行且成功。
  • 孤立肾PN常具挑战性,但可选择性使用TKIs辅助完成。
  • RN偶尔因严重慢性肾病、肿瘤学担忧优先或PN中转而需要。

研究设计与样本

  • 回顾性评估1975-2022年诊断为孤立肾肾肿块的1024例患者。
  • 分析基线特征及病理、功能和生存结局。
  • 干预措施包括PN、RN、冷冻消融(CA)和主动监测(AS)。

主要发现

  • 842例(82%)接受PN,102例(10%)接受CA,54例(5%)接受RN,26例(3%)接受AS。
  • 中位肿瘤大小3.7 cm,中位RENAL评分8,中位随访53个月。
  • PN中95%使用钳夹,中位热缺血时间和冷缺血时间分别为22分钟和45分钟。
  • PN中位术前GFR为57 ml/min/1.73 m2,中位新基线GFR和5年GFR分别为47和48 ml/min/1.73 m2,5年透析-free生存率为97%。
  • 22例(2.1%)透明细胞肾细胞癌且RENAL评分≥10(中位11)患者接受TKIs以促进PN,中位肿瘤体积缩小57%,20例(91%)完成PN。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A renal mass in a solitary kidney (RMSK) has traditionally been managed with partial nephrectomy (PN), although radical nephrectomy (RN) is occasionally required. Most RMSK studies have focused on patients for whom PN was achieved. OBJECTIVE: To provide a comprehensive analysis of the management strategies/outcomes for an RMSK and address knowledge deficits regarding this challenging disorder. DESIGN, SETTING, AND PARTICIPANTS: A total of 1024 patients diagnosed with an RMSK (1975-2022) were retrospectively evaluated. Baseline characteristics and pathologic/functional/survival outcomes were analyzed. INTERVENTION: PN/RN/cryoablation (CA)/active surveillance (AS). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Functional outcomes, perioperative morbidity/mortality, and 5-yr recurrence-free survival (RFS) were evaluated. Kruskal-Wallis and chi-square tests were used to compare cohorts, and log-rank test and Cox proportional hazard model were used for survival analysis. RESULTS AND LIMITATIONS: Of 1024 patients, 842 underwent PN (82%), 102 CA (10%), 54 RN (5%), and 26 AS (3%). The median tumor size and RENAL([R]adius [tumor size as maximal diameter], [E]xophytic/endophytic properties of tumor, [N]earness of tumor deepest portion to collecting system or sinus, [A]nterior [a]/posterior [p] descriptor, and [L]ocation relative to polar lines) score were 3.7 cm and 8, respectively. The median follow-up was 53 mo. For PN, 95% were clamped, and the median warm and cold ischemia times were 22 and 45 min, respectively. For PN, the median preoperative glomerular filtration rate (GFR) was 57 ml/min/1.73 m2, and the median new baseline and 5-yr GFRs were 47 and 48 ml/min/1.73 m2, respectively. Dialysis-free survival for PN was 97% at 5 yr. Twenty-two (2.1%) patients with clear-cell renal cell carcinoma and RENAL score ≥10 (median = 11) received tyrosine kinase inhibitors (TKIs) to facilitate PN, leading to 57% median decrease of tumor volume; PN was accomplished in 20 (91%). Forty-one patients had planned RN (4.0%), most often due to severe pre-existing chronic kidney disease (CKD), and 13 were converted from PN to RN (1.5%). Clavien III-V perioperative complications were observed in 80 (8%) patients and 90-d mortality was 0.6%. Five-year RFS for PN, CA, and RN were 83%, 80%, and 72%, respectively (p = 0.03 for PN vs RN). CONCLUSIONS: Nephron-sparing approaches are feasible and successful in most RMSK patients. PN for an RMSK is often challenging but can be facilitated by selective use of TKIs. RN is occasionally required due to severe CKD, over-riding oncologic concerns, or conversion from PN. This is the first large RMSK study to provide a comprehensive analysis of all management strategies/outcomes. PATIENT SUMMARY: Kidney cancer in a solitary kidney is a major challenge for achieving cancer-free status and avoiding dialysis. Although partial nephrectomy is the principal treatment for a renal mass in a solitary kidney, other options are occasionally required to optimize outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Yasuda Y, Zhang JH, Attawettayanon W, et al. Comprehensive Management of Renal Masses in Solitary Kidneys. Eur Urol Oncol. 2022. PMID: 36517406. doi:10.1016/j.euo.2022.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。